Ipsen : Deal with Sutro Biopharma
>Deal on oncology project at end of pre-clinical phase - Ipsen yesterday signed an exclusive global licensing agreement with Sutro Biopharma for an anti-body drug conjugate targeting solid tumours.Ipsen has secured exclusive global rights for development and commercialisation of STRO-003, an antibody-drug conjugate completing the final stages of pre-clinical development STRO-003 targets the tumour antigen ROR1, which is known for being over-expressed in numerous ...Ipsen is global biotechnology specialty care company. Co. engages in research, development, manufacture and sale of pharmaceutical products for human healthcare. Co.'s product portfolio includes pharmaceutical products marketed around the world to specialists working in its targeted therapeutic areas (oncology, endocrinology, neurology and haematology). These products are specialist care drugs. Co. also markets products in other therapeutic areas including gastroenterology, cardiovascular and cognitive disorders. These products are primary care drugs. Co.'s brand names include Decapeptyl®, Somatuline®, Dysport®, Nutropin Aq®, Smecta®, Forlax®, Nisis®,Adrovance®, Exforge® and Adenuric®.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.